Lowest-Rated StocksLowest-RatedNASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free PTCT Stock Alerts $36.47 -0.73 (-1.96%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$36.25▼$37.7650-Day Range$24.69▼$40.1252-Week Range$17.53▼$45.68Volume844,772 shsAverage Volume967,824 shsMarket Capitalization$2.80 billionP/E RatioN/ADividend YieldN/APrice Target$35.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get PTC Therapeutics alerts: Email Address PTC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.07 Rating ScoreUpside/Downside2.2% Downside$35.67 Price TargetShort InterestHealthy11.63% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.50Based on 25 Articles This WeekInsider TradingSelling Shares$888,907 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.08) to ($3.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector517th out of 931 stocksPharmaceutical Preparations Industry233rd out of 432 stocks 2.0 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 4 buy ratings, 7 hold ratings, and 3 sell ratings.Amount of Analyst CoveragePTC Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.63% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in PTC Therapeutics has recently decreased by 10.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.38. Previous Next 2.5 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for PTC Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $888,907.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of PTC Therapeutics is held by insiders.Read more about PTC Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($5.08) to ($3.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PTC Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About PTC Therapeutics Stock (NASDAQ:PTCT)PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More PTCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTCT Stock News HeadlinesMay 25 at 4:01 PM | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells 20,000 Shares of StockMay 28 at 1:10 PM | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Announces Validation of Sepiapterin European MAAMay 28 at 8:30 AM | prnewswire.comPTC Therapeutics Announces Validation of Sepiapterin European MAAMay 26 at 5:00 AM | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Sells $764,800.00 in StockMay 25 at 5:19 AM | finance.yahoo.comInsider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC Therapeutics Inc (PTCT)May 23, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for PTC Therapeutics, Inc. Decreased by Leerink Partnrs (NASDAQ:PTCT)May 23, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for PTC Therapeutics, Inc. Issued By William Blair (NASDAQ:PTCT)May 22, 2024 | seekingalpha.comPTC Therapeutics: Riding The Regulatory Rollercoaster With TranslarnaMay 22, 2024 | markets.businessinsider.comHold Rating on PTC Therapeutics Amid Regulatory Uncertainty for TranslarnaMay 22, 2024 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) PT Raised to $53.00 at JPMorgan Chase & Co.May 22, 2024 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) PT Raised to $32.00May 22, 2024 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Price Target Increased to $26.00 by Analysts at CitigroupMay 21, 2024 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Given New $46.00 Price Target at Jefferies Financial GroupMay 21, 2024 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Upgraded to "Market Perform" at Raymond JamesMay 20, 2024 | markets.businessinsider.comSell Rating Maintained for PTC Therapeutics Amid Long-Term Revenue Growth ConcernsMay 20, 2024 | markets.businessinsider.comTranslarna’s Uncertain Future: Justifying a Sell Rating for PTC TherapeuticsMay 20, 2024 | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluationMay 20, 2024 | marketwatch.comPTC Therapeutics Shares Rise 21% After European Commission Declines CHMP Opinion on TranslarnaMay 20, 2024 | msn.comPTC Therapeutics rallies 18% on EU authorization update for TranslarnaMay 20, 2024 | msn.comEuropean Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual GuidanceMay 20, 2024 | marketwatch.comPTC Therapeutics Pauses 2024 Revenue Guidance After European Commission Requests Reevaluation of Opinion on ApprovalMay 20, 2024 | markets.businessinsider.comPTC Therapeutics Says European Commission Returns Translarna Opinion To CHMP For Re-evaluationMay 20, 2024 | prnewswire.comPTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluationMay 18, 2024 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Reduce" by BrokeragesMay 14, 2024 | marketwatch.comPTC Therapeutics Gets FDA Priority Review of Upstaza Gene TherapySee More Headlines Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/28/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees988Year FoundedN/APrice Target and Rating Average Stock Price Target$35.67 High Stock Price Target$55.00 Low Stock Price Target$23.00 Potential Upside/Downside-3.3%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($7.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-626,600,000.00 Net Margins-62.45% Pretax Margin-69.62% Return on EquityN/A Return on Assets-28.12% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio1.98 Sales & Book Value Annual Sales$937.82 million Price / Sales3.02 Cash Flow$2.40 per share Price / Cash Flow15.35 Book Value($10.85) per share Price / Book-3.40Miscellaneous Outstanding Shares76,700,000Free Float72,479,000Market Cap$2.83 billion OptionableOptionable Beta0.63 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Matthew B. Klein F.A.C.S. (Age 51)M.D., M.S., CEO & Director Comp: $995.4kDr. Stuart W. Peltz Ph.D. (Age 64)Co-Founder, Senior Consultant & Member of Scientific Advisory Board Comp: $1.54MDr. Allan Steven Jacobson Ph.D. (Age 78)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $145kDr. Neil Almstead Ph.D. (Age 57)Chief Technical Operations Officer Comp: $829.97kMr. Eric Pauwels (Age 63)Chief Business Officer Comp: $847.67kMr. Pierre Gravier M.S. (Age 38)Chief Financial Officer Ms. Christine Utter (Age 46)Senior VP, Chief Accounting Officer & Head of People Services Comp: $595.54kAlex KaneInvestor Relations OfficerMr. Mark Elliott Boulding (Age 63)Executive VP & Chief Legal Officer Comp: $824.09kMs. Jane BajVice President of Corporate CommunicationsMore ExecutivesKey CompetitorsChemoCentryxNASDAQ:CCXIZogenixNASDAQ:ZGNXForty SevenNASDAQ:FTSVSage TherapeuticsNASDAQ:SAGEEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsBurney Co.Bought 42,040 shares on 5/22/2024Ownership: 0.055%Jerome B ZeldisSold 20,000 sharesTotal: $764,800.00 ($38.24/share)Janus Henderson Group PLCBought 1,057,223 shares on 5/16/2024Ownership: 4.785%Jacobs Levy Equity Management Inc.Bought 282,422 shares on 5/16/2024Ownership: 2.094%California State Teachers Retirement SystemSold 3,952 shares on 5/16/2024Ownership: 0.089%View All Insider TransactionsView All Institutional Transactions PTCT Stock Analysis - Frequently Asked Questions Should I buy or sell PTC Therapeutics stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares. View PTCT analyst ratings or view top-rated stocks. What is PTC Therapeutics' stock price target for 2024? 14 brokerages have issued 1-year price targets for PTC Therapeutics' stock. Their PTCT share price targets range from $23.00 to $55.00. On average, they anticipate the company's share price to reach $35.67 in the next twelve months. This suggests that the stock has a possible downside of 2.2%. View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts. How have PTCT shares performed in 2024? PTC Therapeutics' stock was trading at $27.56 at the beginning of the year. Since then, PTCT stock has increased by 32.3% and is now trading at $36.47. View the best growth stocks for 2024 here. When is PTC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our PTCT earnings forecast. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) released its earnings results on Thursday, April, 25th. The biopharmaceutical company reported ($1.20) earnings per share for the quarter, topping analysts' consensus estimates of ($1.21) by $0.01. The biopharmaceutical company earned $210.12 million during the quarter, compared to the consensus estimate of $160.27 million. What ETFs hold PTC Therapeutics' stock? ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), Harbor Human Capital Factor US Small Cap ETF (HAPS), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has PTC Therapeutics issued on next quarter's earnings? PTC Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $606.6 million. What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD). Who are PTC Therapeutics' major shareholders? PTC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.22%), Janus Henderson Group PLC (4.78%), Jacobs Levy Equity Management Inc. (2.09%), Price T Rowe Associates Inc. MD (0.83%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.57%) and Assenagon Asset Management S.A. (0.40%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Jerome B Zeldis, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTCT) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.